The primary estrogen used in menopausal hormone therapy and gender-affirming care — every delivery form, what the modern evidence actually shows, and how to work with a knowledgeable provider.
Estradiol (E2) is the most biologically active estrogen in the human body. Pharmaceutical estradiol is bioidentical — structurally identical to what ovaries produce — and comes in many delivery forms: oral tablets, transdermal patches, topical gels/creams, vaginal preparations, and injectable esters (cypionate, valerate).
Prescription-only in all forms. Used for menopausal symptom management, prevention of postmenopausal osteoporosis, gender-affirming care for transgender women, and fertility treatment support.
FDA approved for multiple indications. Prescription only. Not WADA prohibited for women; context-dependent for men.
Binds ER-α and ER-β throughout the body — reproductive tract, bone, brain, skin, cardiovascular system. Regulates hundreds of downstream genes.
Oral estradiol goes through first-pass liver metabolism, driving up clotting factors and SHBG and raising clot risk. Transdermal delivery bypasses the liver. The largest analysis of this is Vinogradova 2019 in the BMJ (PMID 30626577), a nested case-control study of nearly 80,000 venous thromboembolism cases:
The authors noted transdermal therapy "appears to be underused, with the overwhelming preference still for oral preparations." This is one of the clearest route-of-administration effects in hormone therapy, and it is why modern guidelines favour transdermal for most patients.
Any woman with an intact uterus using estradiol must pair it with progesterone (cyclically or continuously) to protect the endometrium from unopposed estrogen.
| Benefit | Evidence |
|---|---|
| Vasomotor symptoms | Most reliable benefit of menopausal HRT; 70–90% reduction in hot flashes and night sweats |
| Genitourinary syndrome | Vaginal dryness, atrophy, recurrent UTIs respond dramatically to topical or systemic estrogen |
| Bone density | Well established, and one of the few places where fracture reduction (not just density) was demonstrated in the WHI itself |
| Cardiovascular | The "timing hypothesis" has real trial support, on a surrogate marker. ELITE (Hodis 2016, PMID 27028912) randomised women by time since menopause: those under 6 years out had slower carotid intima-media thickening on estradiol (0.0044 vs 0.0078 mm/year, p = 0.008), those 10+ years out had no benefit (interaction p = 0.007). But coronary CT measures — calcium, stenosis, plaque — did not differ in either group. Slower thickening of an artery wall is not the same as fewer heart attacks |
| Mood & sleep | Improved in peri/postmenopausal women with mood-related symptoms |
| Cognitive function | Do not start estrogen to protect cognition. The critical-window idea is a hypothesis; what was actually tested is the opposite case, and it went badly. In WHIMS (PMID 15213206), women 65 and older on conjugated equine estrogens had more probable dementia, pooled HR 1.76 (95% CI 1.19–2.60, p = 0.005), and no reduction in mild cognitive impairment. No trial has shown cognitive protection from starting near menopause |
The Women’s Health Initiative’s original negative findings have been substantially re-interpreted, and the reinterpretation is now the mainstream position rather than a fringe one — see the WHI investigators’ own 2024 review in JAMA (PMID 38691368). Most WHI participants were over 60 and more than 10 years postmenopausal, and took oral conjugated equine estrogens with medroxyprogesterone acetate. That is not modern transdermal estradiol with micronized progesterone, and the risk profiles differ.
The single most reassuring number came later: across 27,347 women followed 18 years (Manson 2017, PMID 28898378), all-cause mortality was 27.1% on hormone therapy versus 27.6% on placebo — HR 0.99 (95% CI 0.94–1.03), with no difference in cardiovascular or cancer mortality either. Whatever WHI showed about individual risks, hormone therapy did not shorten lives.
None of this makes hormone therapy risk-free, and the reinterpretation is sometimes oversold in the other direction. It means the decision belongs to a clinician who knows your history, timing and route — not to a headline from 2002 or a rebuttal to it.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNot medical advice. These are prescription medications. The figures below describe established clinical practice and labelled prescribing information — they are not a recommendation, they do not account for your labs, history, or other medications, and safe use depends on monitoring a page cannot do. Work with a qualified healthcare provider.
Estradiol (sensitive assay), SHBG, LH/FSH (if fertility concerns), lipid panel, annual breast and pelvic exam, mammography per guidelines. Labs are helpful but symptom response is the primary guide — don’t chase numbers at the expense of how the patient feels.
Pre-filled with a typical Estradiol setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Estradiol is a prescription medication. StackTrax does not sell, prescribe, or facilitate purchase of prescription drugs.
Find a clinician who can order baseline lab work, screen for contraindications, monitor your response, and adjust dosing over time. Options to consider:
Before starting, you’ll typically want:
Avoid sources that offer prescription medications without labs, medical history, or licensed-provider oversight. If a telehealth service promises a prescription after a 5-minute questionnaire, that’s a red flag.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreePharmaceutical estradiol comes in many delivery forms: oral tablets (Estrace), transdermal patches (Vivelle-Dot, Climara), topical gels and creams (Divigel, EstroGel), vaginal preparations (cream, ring, tablet), and injectable esters (cypionate, valerate). All are bioidentical — structurally identical to what ovaries produce — and prescription-only in every form. Modern menopause guidelines favor transdermal for most patients because it bypasses first-pass liver metabolism.
Yes, meaningfully. Pharmaceutical estradiol (E2) is bioidentical — structurally identical to the estrogen ovaries produce. Older HRT trials like the Women's Health Initiative predominantly used oral conjugated equine estrogens plus medroxyprogesterone acetate (synthetic progestin), not modern transdermal estradiol plus micronized progesterone. The WHI's original negative findings have been substantially re-interpreted because the risk profiles differ between these regimens, and because most WHI participants were over 60 and more than 10 years postmenopausal.
Injectable estradiol esters (cypionate, valerate) are commonly used in gender-affirming care, and other delivery forms are also used in this context. Dosing is provider-directed and individualized — this guide focuses on the menopausal HRT dosing ranges and does not specify gender-affirming care protocols. For trans women, access typically goes through a gender-affirming care clinic or endocrinologist familiar with the protocols.
It depends on the patient, but the meaningful distinction is oral vs non-oral. Oral estradiol goes through first-pass liver metabolism, which drives up clotting factors and SHBG and increases VTE risk. Transdermal (patch, gel) bypasses the liver and has lower VTE risk while providing the same therapeutic effects. Modern menopause guidelines favor transdermal for most patients. Injectable estradiol esters are used in gender-affirming care and some HRT protocols and are provider-dosed.
Any woman with an intact uterus using estradiol must pair it with progesterone (cyclically or continuously) to protect the endometrium from unopposed estrogen, which can drive endometrial hyperplasia and cancer over time. Women who have had a hysterectomy do not need progesterone for endometrial protection, though some still take it for other benefits like sleep and mood support.
The modern view is much more favorable than the original WHI interpretation. Started before age 60 or within 10 years of menopause (the timing hypothesis), HRT appears cardiovascular-neutral or beneficial; started later, it may be harmful. Active breast cancer, estrogen-sensitive tumors, undiagnosed vaginal bleeding, active thromboembolic disease, recent stroke or MI, and active liver disease are contraindications. Use caution with family history of breast cancer, hypertriglyceridemia (oral form), migraines with aura, and gallbladder disease.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.